Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 12/20 | 0.43 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725243 | 0.93 | POLB (0.49) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL21725232 | 0.85 | POLB (0.46) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL21725238 | 0.84 | TGM2 (0.54) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL24219865 | 0.81 | POLB (0.71) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL24633250 | 0.79 | POLB (0.52) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL21725244 | 0.79 | POLB (0.59) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL21184381 | 0.78 | TGM2 (0.64) | P2RY2P2RY4P2RY6TGM2NT5E | |
| SCHEMBL20762962 | 0.78 | POLB (0.54) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL20762967 | 0.78 | POLB (0.54) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL4968018 | 0.78 | POLB (0.61) | POLBP2RY2P2RY4P2RY6TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | RNGTT, RNMT, CPSF6 | POLB 327/4885P2RY2 2167/4885P2RY4 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.